Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: A prospective study

Keyphrases

• Childhood Acute Lymphoblastic Leukemia 100%
• Minimal Residual Disease 100%
• Clinical Utility 100%
• Sequential Minimal 100%
• Risky Driving 100%
• Disease Levels 39%
• Remission Induction 26%
• Acute Lymphoblastic Leukemia 21%
• Event-free Survival 17%
• Standard Risk 17%
• Clinical Significance 4%
• Clinical Trials 4%
• Risk Classification 4%
• Low-risk Patients 4%
• Clinical High Risk 4%
• Therapeutic Implications 4%
• Newly Diagnosed 4%
• Low Risk 4%
• Laboratory Features 4%
• End of Treatment 4%
• Post-remission 4%
• Treatment Intensity 4%
• Treatment Decisions 4%
• Prognostic Implications 4%
• Guided Therapy 4%
• Clinical Features 4%
• Disease Status 4%
• Research with children 4%
• Research Hospital 4%
• Relapse Risk 4%
• Prognostic Indicator 4%
• Maintenance Treatment 4%
• Maintenance Therapy 4%
• Additional Treatment 4%
• Post-remission Therapy 4%
• Low-risk Group 4%
• Additional Measurement 4%
• Chemotherapy Alone 4%

Medicine and Dentistry

• Minimal Residual Disease 100%
• Acute Lymphoblastic Leukemia 100%
• Prospective Study 100%
• Spontaneous Remission 26%
• Event Free Survival 17%
• Maintenance Therapy 8%
• High Risk Population 4%
• Clinical Trial 4%
• Clinical Significance 4%
• Low Risk Population 4%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Lymphoblastic Leukemia 100%
• Minimal Residual Disease 100%
• Prospective Study 100%
• Remission 34%
• Event Free Survival 17%
• Clinical Trial 4%
• Chemotherapy 4%